FDA red and green lights: March 2026
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
Merck vs Merck in late-line kidney cancer
The group wants to improve on its own Welireg in a new phase 3 trial.
The month ahead: April’s upcoming events
Replimune gets a second chance, while Sarclisa could go subcutaneous.
Allogene looks to consolidate its position
After a delay, the Alpha-3 study faces an April futility analysis.
Arvinas seeks to outdo Astellas
Early data are coming with the KRAS G12D degrader ARV-806.
Incyte’s JAK insurance policy heads for the clinic
A first-in-human trial of PRT12396 starts next month.
Cell therapies head for the clinic
Clinical trial entrants include projects from Gyala, Beijing Biotech and Neowise.
Boehringer takes Imdelltra rival straight to first line
Dareon-Lung-1 will test obrixtamig plus Tecentriq and chemo in small-cell lung cancer.
Gilead puts its Car-T money where its mouth is
KITE-753 is to enter pivotal development – head-to-head against Yescarta.
